Phase II Open-Label Study of Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemo
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Proportion of patients with a confirmed tumor response at any time during the study.
Steven J. O'Day, M.D.
Cancer Institute Medical Group, Inc.
United States: Food and Drug Administration
|Arizona Cancer Center||Tucson, Arizona 85724|
|MD Anderson Cancer Center||Houston, Texas 77030-4096|
|UCLA School of Medicine||Los Angeles, California 900121973|
|University of Pittsburgh||Pittsburgh, Pennsylvania 15261|
|Cancer Institute Medical Group, Inc.||Santa Monica, California 90404|
|University of Alabama at Birmingham-Comprehensive Cancer Ctr.||Birmingham, Alabama 35294-3300|
|Palmetto Hematology Oncology, P.C.||Spartanburg, South Carolina 29303|